TGFB1 and Miyoshi myopathy: However, because TGF-β inhibitors including SB431542 and Ki26894 did not show direct cytotoxic effects on MM cells (Figure 7E), the combination of TGF-β inhibitors with cytoreductive chemotherapeutic agents or bortezomib may further improve the therapeutic efficacy against MM.